ArticleEuropean radiology2026
Prospective evaluation of the semi-quantitative hepatic subcapsular flow score and hepatic capsular retraction sign in the diagnosis of biliary atresia.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo establish a semi-quantitative hepatic subcapsular flow (HSF) score using color Doppler ultrasonography (CDUS) and evaluate the performance of both the HSF score and hepatic capsular retraction (HCR) sign for identifying biliary atresia (BA), while simultaneously correlating with liver fibrosis. MATERIALS AND
methodsThis study prospectively recruited 170 infants (35 BA and 135 non-BA; 124 males and 46 females) with a median age of 50 days (interquartile range 35-71). Multimodal ultrasound (grayscale ultrasound, CDUS, elastography) was utilized to evaluate the HSF score, HCR sign, and established markers (triangular cord [TC] sign, gallbladder, porta hepatis lymph nodes [PHLNs]). Diagnostic performance of individual and combined indicators was evaluated using the receiver operating characteristic curve (ROC). Additionally, correlations were analyzed between HSF score, HCR sign, and serum and histopathological liver fibrosis indicators.
resultsThe HSF score (cutoff ≥2) demonstrated an area under the ROC curve (AUC) of 0.950, superior to the cutoff ≥1 (p = 0.036) and higher (though not significantly) than established markers (all p > 0.05). The HCR sign had a lower AUC than other markers (all p < 0.05) but had high specificity within the studied cohort. It was also associated with higher liver stiffness measurement and fibrosis stage (p < 0.001, p = 0.001).
conclusionThe liver capsule in BA infants undergoes significant morphological changes, which can be assessed using the HSF score and HCR sign. The HSF score provides reliable diagnostic performance for BA. The HCR sign, as a supplementary diagnostic marker, shows high specificity and correlates with the severity of liver fibrosis. These two indicators may support the diagnosis of BA and fibrosis assessment. KEY POINTS: Question Can novel ultrasonographic signs-HSF score and HCR sign-improve the non-invasive diagnosis of BA and fibrosis assessment in cholestatic infants? Findings The HSF score demonstrated excellent diagnostic performance, while the HCR sign offered high specificity and was associated with liver fibrosis. Clinical relevance The HSF score is reliable for diagnosing BA, and the HCR sign serves as a high-specificity marker correlated with the severity of liver fibrosis, thus aiding in early diagnosis and fibrosis assessment.
Indexed as
Identifiers
41832932What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.